0PQ Stock Overview
A biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.65 |
| 52 Week High | US$2.56 |
| 52 Week Low | US$1.07 |
| Beta | 0.30 |
| 1 Month Change | -9.35% |
| 3 Month Change | -5.28% |
| 1 Year Change | -5.18% |
| 3 Year Change | -68.29% |
| 5 Year Change | n/a |
| Change since IPO | -62.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0PQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -0.6% | -1.3% |
| 1Y | -5.2% | -23.5% | 4.0% |
Return vs Industry: 0PQ exceeded the German Biotechs industry which returned -23.5% over the past year.
Return vs Market: 0PQ underperformed the German Market which returned 4% over the past year.
Price Volatility
| 0PQ volatility | |
|---|---|
| 0PQ Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 0PQ's share price has been volatile over the past 3 months.
Volatility Over Time: 0PQ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 157 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.
ProQR Therapeutics N.V. Fundamentals Summary
| 0PQ fundamental statistics | |
|---|---|
| Market cap | €146.79m |
| Earnings (TTM) | -€26.84m |
| Revenue (TTM) | €10.56m |
13.9x
P/S Ratio-5.5x
P/E RatioIs 0PQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0PQ income statement (TTM) | |
|---|---|
| Revenue | €10.56m |
| Cost of Revenue | €0 |
| Gross Profit | €10.56m |
| Other Expenses | €37.40m |
| Earnings | -€26.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -254.28% |
| Debt/Equity Ratio | 12.5% |
How did 0PQ perform over the long term?
See historical performance and comparison